 |
ProTmune (ex vivo Programmed Mobilized Peripheral Blood) |
|---|---|
| Trade Name | |
| Orphan Indication | Graft Versus Host Disease |
| USA Market Approval | USA |
| USA Designation Date | 2016-09-19 00:00:00 |
| Sponsor | Fate Therapeutics;3535 General Atomics Court, Suite 200;San Diego, California, 92121 |
